BM635 is a small molecule endowed with outstanding anti-mycobacterial activity (minimum inhibitory concentration of 0.12 μM against M. tuberculosis H37Rv) identified during a hit-to-lead campaign. Its poor aqueous solubility together with its high lipophilicity led to low exposure in vivo. Indeed, the half-life in vivo of BM635 was 1 h, allowing a reasonable maximum concentration (Cmax = 1.62 μM) and a moderate bioavailability (46%). The present study aimed to develop salt forms of BM635 with pharmaceutically accepted hydrochloric, methanesulphonic, phosphoric, tartaric, and citric acids to overcome these drawbacks. BM635 salts (BM635-HCl, BM635-Mes, BM635-PA, BM635-TA and BM635-CA) were evaluated for physicochemical as well as biopharmaceutical attributes.

Pharmaceutical salt of BM635 with improved bioavailability / Poce, Giovanna; Consalvi, Sara; Cocozza, Martina; Fernandez Menendez, Raquel; Bates, Robert H.; Ortega Muro, Fátima; Barros Aguirre, David; Ballell, Lluis; Biava, Mariangela. - In: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. - ISSN 0928-0987. - STAMPA. - 99:(2017), pp. 17-23. [10.1016/j.ejps.2016.12.003]

Pharmaceutical salt of BM635 with improved bioavailability

POCE, Giovanna;CONSALVI, SARA;COCOZZA, MARTINA;BIAVA, Mariangela
2017

Abstract

BM635 is a small molecule endowed with outstanding anti-mycobacterial activity (minimum inhibitory concentration of 0.12 μM against M. tuberculosis H37Rv) identified during a hit-to-lead campaign. Its poor aqueous solubility together with its high lipophilicity led to low exposure in vivo. Indeed, the half-life in vivo of BM635 was 1 h, allowing a reasonable maximum concentration (Cmax = 1.62 μM) and a moderate bioavailability (46%). The present study aimed to develop salt forms of BM635 with pharmaceutically accepted hydrochloric, methanesulphonic, phosphoric, tartaric, and citric acids to overcome these drawbacks. BM635 salts (BM635-HCl, BM635-Mes, BM635-PA, BM635-TA and BM635-CA) were evaluated for physicochemical as well as biopharmaceutical attributes.
2017
BM635; Drug development; MmpL3; Pharmaceutical salts; Tuberculosis; 3003
01 Pubblicazione su rivista::01a Articolo in rivista
Pharmaceutical salt of BM635 with improved bioavailability / Poce, Giovanna; Consalvi, Sara; Cocozza, Martina; Fernandez Menendez, Raquel; Bates, Robert H.; Ortega Muro, Fátima; Barros Aguirre, David; Ballell, Lluis; Biava, Mariangela. - In: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. - ISSN 0928-0987. - STAMPA. - 99:(2017), pp. 17-23. [10.1016/j.ejps.2016.12.003]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/957091
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact